Add-on Clioquinol in Drug-resistant Childhood Epilepsy: an Exploratory Study
Status:
Active, not recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
In this exploratory trial, the potential anti-seizure activity of clioquinol in a small
cohort of adolescents with drug-resistant epilepsy will be examined. Subjects will be exposed
to clioquinol add-on for a period of maximum 8 weeks (2 weeks low dose, 6 weeks higher dose).
The main hypothesis of the study is that 30% of the included subjects will be responders and
that the median seizure frequency reduction will be at least 30%.